Discovery of a New Scaffold RSK2 Inhibitor With Virtual and Phenotypical Screening
ChemMedChem · 2026-06-26 · 21 (12)
DOI: 10.1002/cmdc.70293 ↗At a glance
Journal article in ChemMedChem, published online on 2026-06-26. Written by Nan Feng and 8 co-authors. Institution: Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, P. R. China. Major MEDLINE topics: Ribosomal Protein S6 Kinases, 90-kDa, Protein Kinase Inhibitors, Antineoplastic Agents, Drug Discovery. 35 references. Funded by: National Science and Technology Major Project, National Natural Science Foundation of China, Young Scientists Fund of the National Natural Science Foundation of China.
Abstract (original language)
Ribosomal S6 kinase (RSK2) is regarded as an important target for the treatment of breast and ovarian cancers. However, most reported RSK2 inhibitors suffer from insufficient selectivity and unfavorable pharmacokinetic properties due to their similar chemical scaffolds. Therefore, the discovery of novel RSK2 inhibitors with high potency, selectivity, and desirable drug‐like properties remains highly desirable. In this work, we established a virtual screening workflow combining pharmacophore modeling, molecular docking, and molecular dynamics simulations. By screening the Chemdiv database (1.6 million compounds), 39 potential RSK2 inhibitors were obtained. Further phenotypic screening identified compound M39 as a promising cell‐active RSK2 inhibitor. Surface plasmon resonance assays verified that M39 binds to RSK2 with a Kd value of 156 nM. M39 inhibits the catalytic activity of RSK2 by suppressing YB1 phosphorylation and shows stronger anti‐tumor activity than the control LJH685 in breast and ovarian cancer cells. In summary, M39 features a unique chemical scaffold and serves as a promising lead compound for further optimization, as well as a useful chemical tool for exploring the biological functions of RSK2.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, P. R. China.
- Department of Cardiology, West China Hospital, Sichuan University, Chengdu, P. R. China.
- Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, P. R. China.
ORCID profiles: Nan Feng, Keyi Liu, Shilong Jiang, Qing Zhang, Youchao Deng, Dongsheng Cao
Funding
- National Science and Technology Major Project
- National Natural Science Foundation of China
- Young Scientists Fund of the National Natural Science Foundation of China
- The Young Scientists Fund of Natural Science Foundation of Hunan Province of China
Cite
APA
Feng, N., Ning, Q., Liu, K., Li, H., Jiang, S., Zhang, Q., Jiang, D., Deng, Y., & Cao, D. (2026). Discovery of a New Scaffold RSK2 Inhibitor With Virtual and Phenotypical Screening. ChemMedChem, 21(12). https://doi.org/10.1002/cmdc.70293
Vancouver
Feng N, Ning Q, Liu K, Li H, Jiang S, Zhang Q, et al. Discovery of a New Scaffold RSK2 Inhibitor With Virtual and Phenotypical Screening. ChemMedChem. 2026;21(12). doi:10.1002/cmdc.70293
BibTeX
@article{Feng2026,
author = {Feng, Nan and Ning, Qiongru and Liu, Keyi and Li, Hui and Jiang, Shilong and Zhang, Qing and Jiang, Dejun and Deng, Youchao and Cao, Dongsheng},
title = {Discovery of a New Scaffold RSK2 Inhibitor With Virtual and Phenotypical Screening},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {12},
doi = {10.1002/cmdc.70293}
}
EUVIMED